Health information to help you understand symptoms. It isn't a diagnosis.
Check symptoms

Research deep dives

ALS genetics, and who should be tested

Last reviewed November 17, 2026. OwieClear editorial team. Waiting for clinician review. Not medical advice. Talk with your doctor about your own care.

About nine in ten people with ALS have no family history of it. That used to mean genetic testing was reserved for the other one in ten.

Two things changed that. Genes are found in a meaningful minority of apparently sporadic cases, and one gene now has a treatment aimed specifically at it, which makes the result actionable rather than merely informative.

Related pages: ALS (amyotrophic lateral sclerosis)

The bottom line

What we know
  • Roughly 90 percent of ALS is sporadic and 10 percent familial.
  • C9orf72 is the most common genetic cause and links ALS with frontotemporal dementia.
  • A targeted therapy exists for SOD1-associated ALS.
  • GINA does not cover life, disability or long-term care insurance.
What is still open
  • Why penetrance varies so much within families carrying the same variant.
  • What proportion of sporadic ALS has a genetic contribution not yet identified.

The story, step by step

  1. 1. The split ()
  2. 2. The genes ()
  3. 3. Who gets tested ()
  4. 4. Relatives ()
What the evidence labels mean
GuidelineAn official recommendation from an expert group after weighing all the evidence.
Review of many studiesCombines the results of many studies (a systematic review or meta-analysis).
Randomized trialPeople were randomly given a treatment or a comparison, the best way to test cause and effect.
Large observational studyFollows many people over time. Shows strong links, but not always cause and effect.
Small or early studyA small study, case series, or first results. Needs to be confirmed.
Lab or animal studyDone in cells or animals. May not apply to people.
Part 1 of 4

Sporadic, familial, and the blur between

Review of many studies

What happens

What the categories actually mean.

What the research shows

  • Familial ALS means ALS plus a family history, roughly 10 percent of cases. Sporadic means no known family history, roughly 90 percent.
  • The split is less clean than it sounds. A recognized ALS gene is found in a proportion of people with no family history, because penetrance is incomplete, families are small, and relatives may have died of other causes first.
  • Family history can also be hidden. A grandparent recorded as having had a stroke or dementia may have had ALS or frontotemporal dementia, which share genes.
  • Multi-step models suggest ALS requires several hits, with genetic variants supplying some of the steps and other factors supplying the rest, which is why a gene raises risk without guaranteeing disease.
  • Having a relative with ALS raises your risk above the general population and still leaves it low in absolute terms, and a genetic counsellor can put a number on it for your specific family.

Why it matters

The practical consequence is that a negative family history no longer rules out a genetic cause.

What's still uncertain

  • What proportion of sporadic ALS has an undiscovered genetic contribution.

Read more

Next: The genes

Part 2 of 4

C9orf72, SOD1 and the rest

Review of many studies

What happens

The main ones, and what they mean.

What the research shows

  • C9orf72 is the most common known genetic cause, a repeat expansion accounting for a large share of familial ALS and a meaningful share of apparently sporadic cases. It also causes frontotemporal dementia, and families often contain both.
  • SOD1 was the first ALS gene identified, in 1993. It causes a smaller share of cases and is now the most clinically consequential, because a targeted therapy exists for it.
  • TARDBP and FUS account for smaller proportions, and dozens of other genes contribute rarely.
  • Penetrance varies. Some variants cause ALS in nearly everyone who carries them; others raise risk without certainty, and age at onset varies widely within a single family.
  • The C9orf72 link to frontotemporal dementia matters practically, because cognitive and behavioural change occurs in a proportion of people with ALS and is more likely with this gene. Knowing changes what the family watches for.
  • A positive result does not predict how the disease will behave in a given person, beyond broad patterns.

Why it matters

Knowing which gene is involved increasingly changes something: trial eligibility, surveillance in relatives, and for SOD1 the treatment itself.

What's still uncertain

  • Why the same variant produces ALS at 40 in one relative and 70 in another.

Read more

Next: Who gets tested

Part 3 of 4

Why this changed recently

Review of many studies

What happens

The shift from familial-only to everyone.

What the research shows

  • Guidance has moved toward offering genetic testing to everyone diagnosed with ALS, not only those with a family history.
  • The main driver is tofersen, an antisense therapy approved for SOD1-associated ALS, which means a SOD1 result changes treatment rather than only explaining things.
  • The second driver is trials. Gene-targeted trials, including for C9orf72, require knowing the genotype, and eligibility windows are often early in the disease.
  • The third is family. A result allows relatives to make informed decisions about predictive testing and reproductive choices.
  • Testing should go alongside genetic counselling rather than being handed over as a lab result, because the implications extend to people who did not ask for them.
  • Declining testing is a legitimate choice, and so is testing now and deferring the question of telling relatives.

Why it matters

A test that was once academic is now, for a minority, the difference between having a targeted treatment available and not.

What's still uncertain

  • How many people with apparently sporadic ALS carry actionable variants, which is being clarified as testing broadens.

Read more

Next: Relatives

Part 4 of 4

Predictive testing, and the insurance gap

Review of many studies

What happens

The decision that affects people who do not have the disease.

What the research shows

  • Predictive testing in an unaffected relative is offered through genetic counselling, usually over several appointments, because the result cannot be given back.
  • People test for very different reasons: planning, reproductive decisions, trial participation, or simply not wanting to live with the question. All are valid, and so is choosing not to know.
  • In the United States, GINA prohibits discrimination based on genetic information in health insurance and employment. It does not cover life insurance, disability insurance or long-term care insurance, and several states add protections that vary.
  • That gap is the single most important practical fact in this area, and the brief that prompted this page cites GINA without it. Many counsellors advise arranging life and disability cover before predictive testing.
  • Reproductive options exist for people carrying a known variant, including preimplantation genetic testing and prenatal diagnosis, and are worth discussing before rather than during a pregnancy.
  • Presymptomatic research cohorts exist and allow carriers to contribute to trials aimed at preventing onset, which is where this field is heading.
  • Testing a child for an adult-onset condition is generally not done, for reasons genetic counsellors will explain.

Why it matters

The insurance point is the one people most often learn too late, and it is irreversible in a way the test result is not.

What's still uncertain

  • Whether treating carriers before symptoms begin will prevent ALS, which presymptomatic trials are testing now.

Read more

More plain-language reading

See something wrong or unclear on this page? Suggest a correction. OwieClear is for education only and isn't medical advice.